Education
About Us
Working with TipRanks
Follow Us
MaaT Pharma (FR:MAAT)
:MAAT
MAAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.40 - €9.96
Previous CloseN/A
Volume44.42K
Average Volume (3M)13.88K
Market Cap
€73.68M
Enterprise Value€69.61M
Total Cash (Recent Filing)€20.22M
Total Debt (Recent Filing)€15.96M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Sep 16, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding16,115,252
10 Day Avg. Volume30,748
30 Day Avg. Volume13,878
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.19
Price to Sales (P/S)0.00
P/FCF Ratio-3.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.00Price Target Upside287.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MaaT Pharma News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMaaT Pharma has released its FY24 results, with €3.2m (+44% vs. 2023) in revenue reflecting yet another year of increased EAP demand, boosted by the strong P3 data.
Regulatory ProgressA Marketing Authorization Application submission to the EMA for MaaT013 approval in Europe is anticipated as a positive catalyst.
Safety And EfficacyRobust positive Phase 3 data support MaaT013 efficacy and safety, and de-risk a planned follow-on Phase 3 study in the U.S.
Bears Say
Clinical TrialsRisks to the investment thesis include failure of clinical trials, regulatory requirements for additional studies, and the potential need to raise additional funds under poor market conditions.
Financial RisksThe pressing issue is to secure additional funding, as the company's cash position only extends to the second quarter of 2025.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
1.03% Other Institutional Investors
98.35% Public Companies and
Individual Investors
MAAT FAQ
What was MaaT Pharma’s price range in the past 12 months?
MaaT Pharma lowest stock price was €4.40 and its highest was €9.96 in the past 12 months.
What is MaaT Pharma’s market cap?
MaaT Pharma’s market cap is €73.68M.
When is MaaT Pharma’s upcoming earnings report date?
MaaT Pharma’s upcoming earnings report date is Sep 16, 2025 which is in 59 days.
How were MaaT Pharma’s earnings last quarter?
Currently, no data Available
Is MaaT Pharma overvalued?
According to Wall Street analysts MaaT Pharma’s price is currently Undervalued.
Does MaaT Pharma pay dividends?
MaaT Pharma does not currently pay dividends.
What is MaaT Pharma’s EPS estimate?
MaaT Pharma’s EPS estimate is -1.06.
How many shares outstanding does MaaT Pharma have?
MaaT Pharma has 16,115,252 shares outstanding.
What happened to MaaT Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MaaT Pharma?
Currently, no hedge funds are holding shares in FR:MAAT
Company Description
MaaT Pharma
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MAAT Stock 12 Month Forecast
Average Price Target
€18.00
▲(287.10%Upside)